Speaker Profile

Partner, Menlo Ventures

Greg invests in teams trying to solve major problems in life science and digital health, with a special interest in novel therapeutic platforms, digital health, and transformative technologies. Prior to entering investing, Greg served for more than 20 years in senior executive and entrepreneurial roles in life sciences and digital health. He was CEO and co-founder of two startups (Biodesy in protein analysis & therapeutics and PyrAmes in digital health & remote monitoring). At Roche/Ventana, Greg led a global market-leading cancer diagnostic assay business, serving 20 million patients and delivering $500 million revenue per year. Greg was also an EIR at Illumina Ventures, the first healthcare EIR at GE, VP/GM at Affymetrix, and consultant for McKinsey. Greg received his bachelor’s degree in molecular biology (summa cum laude) from Princeton and his MBA from Stanford. Greg is an Aspen Health Innovators Fellow and a member of the Aspen Global Leadership network.

 Session Abstract – PMWC 2022 Silicon Valley

Track 2 , June 30

This session outlines current challenges and opportunities related to the use of AI to advance therapeutic development and care delivery, with a special focus on medical imaging.